GlassScriptPhysician profile
Drew W Harper
NPI 1598153157
$1,516.71
in general payments reported to CMS, 2019-2025
24 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $352 · 2023: $214 · 2024: $258 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $338.88 | 2022-2025 | Variax, Triathlon, Augment Injectable |
| Amgen INC. | $188.65 | 2021-2023 | Evenity, Prolia |
| Vertex Pharmaceuticals Incorporated | $148.14 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $102.30 | 2021-2025 | Zilretta, Iovera, Exparel |
| Horizon Therapeutics Plc | $86.95 | 2021-2022 | |
| Radius Health, INC. | $78.32 | 2021-2025 | Tymlos |
| Bioventus LLC | $63.89 | 2021-2025 | Exogen Ultrasound Bone Healing System |
| Djo, LLC | $61.38 | 2024-2025 | Cmf |
| Boston Scientific Corporation | $58.15 | 2025 | Cds - Mct/Cem Monitoring |
| Heron Therapeutics, INC. | $55.40 | 2024 | Zynrelef |
| Ferring Pharmaceuticals INC. | $55.14 | 2023-2024 | Euflexxa |
| Astrazeneca Pharmaceuticals LP | $52.02 | 2023-2025 | Wainua |
| Innovation Technologies INC | $31.86 | 2025 | Irrisept |
| Organogenesis INC. | $31.05 | 2025 | Puraply Wound Matrix |
| Pacira Therapeutics, INC. | $22.46 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.00 | 2025 | Mounjaro |
| Ethicon US, LLC | $19.39 | 2024 | Vistaseal |
| Endo Pharmaceuticals INC. | $16.58 | 2023 | Xiaflex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.71 | 2023 | Jardiance |
| Endo USA, INC. | $15.28 | 2025 | Xiaflex |
| Convatec INC. | $14.37 | 2022 | |
| Midsouth Orthopedics INC. | $14.32 | 2023 | |
| Depuy Synthes Sales INC. | $12.97 | 2021 | |
| Triad Life Sciences INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.